Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1974 1
1975 3
1976 1
1979 1
1980 2
1981 2
1982 7
1983 5
1984 7
1985 7
1986 5
1987 14
1988 14
1989 27
1990 26
1991 26
1992 47
1993 56
1994 69
1995 53
1996 64
1997 77
1998 75
1999 78
2000 66
2001 76
2002 89
2003 90
2004 115
2005 124
2006 131
2007 143
2008 174
2009 152
2010 159
2011 170
2012 214
2013 202
2014 232
2015 257
2016 242
2017 280
2018 291
2019 316
2020 362
2021 429
2022 529
2023 486
2024 203

Text availability

Article attribute

Article type

Publication date

Search Results

5,589 results

Results by year

Filters applied: . Clear all
Page 1
Autoimmune Encephalitis: Current Knowledge on Subtypes, Disease Mechanisms and Treatment.
Nissen MS, Ryding M, Meyer M, Blaabjerg M. Nissen MS, et al. CNS Neurol Disord Drug Targets. 2020;19(8):584-598. doi: 10.2174/1871527319666200708133103. CNS Neurol Disord Drug Targets. 2020. PMID: 32640967 Review.
Autoimmune Encephalitides (AE) comprises a group of diseases with antibodies against neuronal synaptic and cell surface antigens. Since the discovery of the most common subtype, NMethyl- D-Aspartate (NMDA) receptor encephalitis, an astonishing number of novel disease-causi …
Autoimmune Encephalitides (AE) comprises a group of diseases with antibodies against neuronal synaptic and cell surface antigens. Sin …
Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial.
Qiu MZ, Zhang Y, Guo Y, Guo W, Nian W, Liao W, Xu Z, Zhang W, Zhao HY, Wei X, Xue L, Tang W, Wu Y, Ren G, Wang L, Xi J, Jin Y, Li H, Hu C, Xu RH. Qiu MZ, et al. JAMA Oncol. 2022 Jul 1;8(7):1042-1046. doi: 10.1001/jamaoncol.2022.0503. JAMA Oncol. 2022. PMID: 35511148 Free PMC article. Clinical Trial.
IMPORTANCE: The antibody drug conjugate drug MRG003 comprises an anti-epidermal growth factor receptor (EGFR) humanized immunoglobulin G1 monoclonal antibody that is conjugated with monomethyl auristatin E via a valine-citrulline linker. ...
IMPORTANCE: The antibody drug conjugate drug MRG003 comprises an anti-epidermal growth factor receptor (EGFR) humanized immuno …
Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer.
Zhao S, Zhuang W, Han B, Song Z, Guo W, Luo F, Wu L, Hu Y, Wang H, Dong X, Jiang D, Wang M, Miao L, Wang Q, Zhang J, Fu Z, Huang Y, Xu C, Hu L, Li L, Hu R, Yang Y, Li M, Yang X, Zhang L, Huang Y, Fang W. Zhao S, et al. Nat Commun. 2023 Jun 12;14(1):3468. doi: 10.1038/s41467-023-39139-4. Nat Commun. 2023. PMID: 37308490 Free PMC article. Clinical Trial.
Here we report the activity, tolerability, potential mechanisms of response and resistance for dual targeting EGFR 20ins with JMT101 (anti-EGFR monoclonal antibody) plus osimertinib from preclinical models and an open label, multi-center phase 1b trial (NCT04448379) …
Here we report the activity, tolerability, potential mechanisms of response and resistance for dual targeting EGFR 20ins with JMT101 (ant …
Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals.
Kozma GT, Shimizu T, Ishida T, Szebeni J. Kozma GT, et al. Adv Drug Deliv Rev. 2020;154-155:163-175. doi: 10.1016/j.addr.2020.07.024. Epub 2020 Aug 1. Adv Drug Deliv Rev. 2020. PMID: 32745496 Free article. Review.
Nevertheless, these drugs and agents are often immunogenic, triggering the rise of anti-drug antibodies (ADAs). Among these ADAs, anti-PEG IgG and IgM were shown to account for efficacy loss due to accelerated blood clearance of the drug (ABC phenomenon) and …
Nevertheless, these drugs and agents are often immunogenic, triggering the rise of anti-drug antibodies (ADAs). Among these AD …
Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.
Hu J, Sun C, Lu J, Zhao C, Lin J. Hu J, et al. J Neurol. 2022 Mar;269(3):1250-1263. doi: 10.1007/s00415-021-10646-y. Epub 2021 Jun 12. J Neurol. 2022. PMID: 34120208 Review.
BACKGROUND: Current standard treatment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) has been proved effective, but it is poorly effective in refractory patients and unclear for anti-IgG4 antibody-associated CIDP. Rituximab is a B cell-depletin …
BACKGROUND: Current standard treatment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) has been proved effective, but it …
Structure-based engineering of a novel CD3epsilon-targeting antibody for reduced polyreactivity.
Liu CY, Ahonen CL, Brown ME, Zhou L, Welin M, Krauland EM, Pejchal R, Widboom PF, Battles MB. Liu CY, et al. MAbs. 2023 Jan-Dec;15(1):2189974. doi: 10.1080/19420862.2023.2189974. MAbs. 2023. PMID: 36991534 Free PMC article.
Bispecific antibodies continue to represent a growth area for antibody therapeutics, with roughly a third of molecules in clinical development being T-cell engagers that use an anti-CD3 binding arm. ...Using insights from the crystal structure of anti- …
Bispecific antibodies continue to represent a growth area for antibody therapeutics, with roughly a third of molecules in clin …
Neuronal uptake of anti-Hu antibody, but not anti-Ri antibody, leads to cell death in brain slice cultures.
Greenlee JE, Clawson SA, Hill KE, Wood B, Clardy SL, Tsunoda I, Jaskowski TD, Carlson NG. Greenlee JE, et al. J Neuroinflammation. 2014 Sep 17;11:160. doi: 10.1186/s12974-014-0160-0. J Neuroinflammation. 2014. PMID: 25228406 Free PMC article.
METHODS: To study the effect of anti-Hu and anti-Ri antibodies on neurons, we incubated rat hippocampal and cerebellar slice cultures with anti-Hu or anti-Ri sera from multiple patients. ...To test the specificity of anti- …
METHODS: To study the effect of anti-Hu and anti-Ri antibodies on neurons, we incubated rat hippocampal and cere …
Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies.
Chew HY, De Lima PO, Gonzalez Cruz JL, Banushi B, Echejoh G, Hu L, Joseph SR, Lum B, Rae J, O'Donnell JS, Merida de Long L, Okano S, King B, Barry R, Moi D, Mazzieri R, Thomas R, Souza-Fonseca-Guimaraes F, Foote M, McCluskey A, Robinson PJ, Frazer IH, Saunders NA, Parton RG, Dolcetti R, Cuff K, Martin JH, Panizza B, Walpole E, Wells JW, Simpson F. Chew HY, et al. Cell. 2020 Mar 5;180(5):895-914.e27. doi: 10.1016/j.cell.2020.02.019. Cell. 2020. PMID: 32142680 Free article.
A safe and controlled manipulation of endocytosis in vivo may have disruptive therapeutic potential. Here, we demonstrate that the anti-emetic/anti-psychotic prochlorperazine can be repurposed to reversibly inhibit the in vivo endocytosis of membrane proteins target …
A safe and controlled manipulation of endocytosis in vivo may have disruptive therapeutic potential. Here, we demonstrate that the anti …
Nuclear localization of anti-Hu antibody is not associated with in vitro cytotoxicity.
Hormigo A, Lieberman F. Hormigo A, et al. J Neuroimmunol. 1994 Dec;55(2):205-12. doi: 10.1016/0165-5728(94)90011-6. J Neuroimmunol. 1994. PMID: 7829670
IgG fractions of sera containing anti-Hu antibodies or control sera were incubated with Hu-positive and Hu-negative cell lines. ...Anti-Hu IgG did not affect proliferation of Hu-positive cells. Anti-Hu antib …
IgG fractions of sera containing anti-Hu antibodies or control sera were incubated with Hu-positive and Hu …
5,589 results